Following a public comment period, the Federal Trade Commission has approved a final order settling charges that national kidney-dialysis chain U.S. Renal Care, Inc.’s $640 million acquisition of competitor DSI Renal from DSI Renal’s ultimate parent company, Dialysis Parent, LLC, would be anticompetitive.
Under the order, first announced in December 2015, Rangers Renal Holdings LP, the parent company of U.S. Renal Care, Inc., and Dialysis Parent, LLC are required to divest the three DSI Renal outpatient dialysis clinics in Laredo to Satellite Healthcare, Inc.
The Commission vote approving the final order was 4-0. (FTC File No. 151 0215; the staff contact is Lisa De Marchi Sleigh, Bureau of Competition, 202-326-2535)
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.
Office of Public Affairs